Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Scand J Med Sci Sports ; 28(8): 1925-1933, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29668082

RESUMEN

Exercise training reduces the side effects of cancer treatments; however, the stress hormone response to acute exercise during prostate cancer (PCa) treatment is unclear. The study purpose was to examine the effects of acute exercise on circulating cortisol, epinephrine (Epi), and norepinephrine (NE) concentrations during PCa treatment with and without androgen deprivation therapy (ADT). Men with PCa (n = 11), with PCa on ADT (n = 11), and with non-cancer controls (n = 8) had blood samples for stress hormones collected before and immediately (0 hour), 2 hours, and 24 hours after 45 minutes of intermittent cycling at 60% of peak wattage. NE increased by 385% (P < .001) at 0 hour and remained elevated at 2 hours (P < .05) with no group differences. Overall, cortisol significantly increased at 0 hour (36%, P < .012) and then significantly decreased below baseline at 2 hours (-24%, P < .001) before returning to resting levels at 24 hours. Cortisol levels during ADT were 32% lower than PCa (P = .006) with no differences vs controls. Epi increased immediately after exercise more in controls (817%, P < .001) than with ADT (700%) and PCa (333%) patients, and both cancer groups' absolute levels were attenuated relative to controls (ADT: -54%, PCa: -52%, P = .004). Compared with age-matched controls, PCa and ADT patients exhibited similar stress hormone responses with acute exercise for NE and cortisol but an attenuated EPI response that suggests altered adrenal function. Future studies should examine the physical stress of multiple exercise bouts to verify these findings and to explore the functional hormonal effects, such as immune and metabolic responses, during cancer treatment.


Asunto(s)
Epinefrina/sangre , Ejercicio Físico/fisiología , Hidrocortisona/sangre , Norepinefrina/sangre , Neoplasias de la Próstata/sangre , Anciano , Antagonistas de Andrógenos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Consumo de Oxígeno , Neoplasias de la Próstata/tratamiento farmacológico
2.
Br J Cancer ; 99(4): 632-8, 2008 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-18682714

RESUMEN

Dose fractionation has been proposed as a method to improve the therapeutic ratio of radioimmunotherapy (RIT). This study compared a single administration of 7.4 MBq 131I-anti-CEA antibody given on day 1 with the same total activity given as fractionated treatment: 3.7 MBq (days 1 and 3), 2.4 MBq (days 1, 3, and 5) or 1.8 MBq (days 1, 3, 5, and 8). Studies in nude mice, bearing the human colorectal xenograft LS174T, showed that increasing the fractionation significantly reduced the efficacy of therapy. Fractionation was associated with a decrease in systemic toxicity as assessed by weight, but did not lead to any significant decrease in acute haematological toxicity. Similarly, no significant decrease in marrow toxicity, as assessed by colony-forming unit assays for granulocytes and macrophages (CFUgm), was seen. However, there was a significant depression of CFUgm counts when all treated animals were compared with untreated controls, suggesting that treatment did suppress marrow function. In conclusion, in this tumour model system, fractionated RIT causes less systemic toxicity, but is also less effective at treating tumours.


Asunto(s)
Adenocarcinoma/radioterapia , Antígeno Carcinoembrionario/inmunología , Neoplasias Colorrectales/radioterapia , Enfermedades Hematológicas/etiología , Radioisótopos de Yodo/uso terapéutico , Radioinmunoterapia , Adenocarcinoma/secundario , Animales , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales/uso terapéutico , Médula Ósea/efectos de la radiación , Ensayo de Unidades Formadoras de Colonias , Neoplasias Colorrectales/patología , Fraccionamiento de la Dosis de Radiación , Femenino , Granulocitos/efectos de la radiación , Humanos , Radioisótopos de Yodo/farmacocinética , Macrófagos/efectos de la radiación , Ratones , Ratones Desnudos , Distribución Tisular , Resultado del Tratamiento , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Br J Radiol ; 77(922): 811-20, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15482992

RESUMEN

In the treatment of early breast cancer adjuvant irradiation improves local control following both mastectomy and breast-conserving surgery. For women at high risk of relapse it also increases survival. Breast radiotherapy is usually given using simple planning techniques and serious morbidity is unusual. The greatest concern following adjuvant breast irradiation is of an increase in cardiovascular mortality after 15-20 years. New techniques of breast irradiation including conformal radiotherapy and intensity-modulated radiotherapy (IMRT) have been shown to reduce cardiac and lung irradiation. In addition, improved dosimetry within the breast may improve both local control and cosmesis. To replace current radiotherapy techniques with those requiring more complex planning would demand an increase in resources including both machinery and staff. In this review we outline the indications and benefits of breast radiotherapy along with the planning process. Technical advances are discussed within the context of improving outcome at a time of limited national resources.


Asunto(s)
Neoplasias de la Mama/radioterapia , Carcinoma Ductal de Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/cirugía , Femenino , Humanos , Metástasis Linfática/radioterapia , Mastectomía , Traumatismos por Radiación/etiología , Traumatismos por Radiación/prevención & control , Dosificación Radioterapéutica , Radioterapia Adyuvante , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...